FDA approves darolutamide for metastatic prostate cancer subset

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.
Darolutamide (Nubeqa, Bayer) is an androgen receptor (AR) inhibitor designed to inhibit androgen binding, AR nuclear translocation and AR-mediated transcription.
The FDA based the approval on results of the randomized phase 3 ARASENS trial, which included 1,306 men with newly diagnosed metastatic hormone-sensitive prostate cancer.
Researchers assigned men to androgen deprivation therapy and docetaxel plus either 600 mg darolutamide twice daily or placebo.
OS served as the

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.
Darolutamide (Nubeqa, Bayer) is an androgen receptor (AR) inhibitor designed to inhibit androgen binding, AR nuclear translocation and AR-mediated transcription.
The FDA based the approval on results of the randomized phase 3 ARASENS trial, which included 1,306 men with newly diagnosed metastatic hormone-sensitive prostate cancer.
Researchers assigned men to androgen deprivation therapy and docetaxel plus either 600 mg darolutamide twice daily or placebo.
OS served as the